BEONE MEDICINES LTD. (ONC)
A FDA dos EUA concede revisão prioritária ao TEVIMBRA da BeOne Medicines para o tratamento de primeira linha do adenocarcinoma gastroesofágico HER2+
A FDA dos EUA concede revisão prioritária ao TEVIMBRA da BeOne Medicines para o tratamento de primeira linha do adenocarcinoma gastroesofágico HER2+
LFDA statunitense concede la revisione prioritaria a TEVIMBRA di BeOne Medicines nel trattamento di prima linea delladenocarcinoma gastroesofageo HER2 positivo
Amerikaanse FDA kent Priority Review toe aan BeOne Medicines’ TEVIMBRA in eerstelijns HER2+ GEA
La FDA américaine accorde une évaluation prioritaire au TEVIMBRA de BeOne Medicines dans le traitement de première intention de l’adénocarcinome gastro-œsophagien HER2+
Die US-amerikanische FDA bewilligt die vorrangige Prüfung von TEVIMBRA von BeOne Medicines als Erstlinienbehandlung bei HER2+ GEA
Deadline Approaching: LKQ Corporation (LKQ) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
Gartner, Inc. (IT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Mise à disposition du Document d’Enregistrement Universel 2025
Securities Fraud Investigation Into Regencell Bioscience Holdings Limited (RGC) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
New Era Energy & Digital, Inc. (NUAI) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit